ALT — Altimmune, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1326190 ·
Last close
$2.93
Market Cap
$569.81M
52W High
$4.47
52W Low
$2.56
ADV30
4,591,242
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -24,244,000 | -22,563,000 | 335,630,000 | 97,601,000 | 51,643,000 |
| Dec 2025 | 26,000 | — | -28,893,000 | -27,358,000 | 279,929,000 | 43,760,000 | 55,037,000 |
| Sep 2025 | 5,000 | — | -20,859,000 | -19,014,000 | 218,447,000 | 61,236,000 | 32,846,000 |
| Jun 2025 | 5,000 | — | -22,922,000 | -22,146,000 | 190,350,000 | 183,105,000 | 28,983,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-67,535,000
Investing CF
$-132,473,000
Financing CF
$206,842,000
CapEx
$-1,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.01
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-649,483,000
Inventory
—
Receivables
$1,737,000
ST Investments
$229,696,000
EBIT TTM
$-87,138,000
Pretax Income TTM
$-88,774,000
Interest Exp TTM
$1,636,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,000
EBITDA
$-96,103,000
Free Cash Flow
$-42,502,000
Enterprise Value
$268,282,048
Total Cash
$331,540,000
Total Debt
$35,847,000
Shares Out
194,474,154
Trailing EPS
$-0.92
Book Value
$2.18
ROE
-42.7%
ROA
-24.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 41,000 | -94,489,000 | -88,093,000 | 279,929,000 | 55,037,000 | — | -67,535,000 |
| Dec 2024 | 20,000 | -103,172,000 | -95,059,000 | 139,306,000 | 15,798,000 | — | -79,848,000 |
| Dec 2023 | 426,000 | -83,510,000 | -88,447,000 | 210,640,000 | 16,541,000 | — | -75,810,000 |
| Dec 2022 | -68,000 | -87,740,000 | -84,713,000 | 206,928,000 | 21,635,000 | — | -62,586,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$371,000
NetIncome TTM
$-90,548,000
OpCashFlow TTM
$0
Assets (Latest)
$139,306,000
Forward EPS
$-0.90
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $4.00 · spot: $2.93 · call volume: 621 · put volume: 230
Expected Move to 2027-01-15:
±$1.67
(57.00%) —
implied range
$1.26 –
$4.60
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARVN | ARVINAS, INC. | $575.53M | $8.92 | — |
| GYRE | GYRE THERAPEUTICS, INC. | $576.35M | $5.94 | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $561.09M | $20.35 | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $595.09M | $17.06 | — |
| VREOF | Vireo Growth Inc. | $598.52M | $0.44 | — |
News headlines (Yahoo Finance, 1h cache)
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
2026-05-22 16:14 · Yahoo
Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
2026-05-14 14:42 · Yahoo
Altimmune Inc (ALT) Q1 2026 Earnings Call Highlights: Strong Cash Position and Strategic ...
2026-05-13 23:01 · Yahoo
Altimmune (ALT) Q1 2026 Earnings Transcript
2026-05-13 20:59 · Yahoo
Altimmune, Inc. Q1 2026 Earnings Call Summary
2026-05-13 20:45 · Yahoo
Altimmune Q1 Earnings Call Highlights
2026-05-13 14:07 · Yahoo
Altimmune Q1 2026 Earnings Call: Complete Transcript
2026-05-13 13:44 · Yahoo
Altimmune shares climb after first-quarter loss beats expectations (ALT)
2026-05-13 13:29 · Yahoo
Altimmune Announces First Quarter 2026 Financial Results and Business Update
2026-05-13 11:30 · Yahoo
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
2026-05-13 11:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.